Publications
NIBIOs employees contribute to several hundred scientific articles and research reports every year. You can browse or search in our collection which contains references and links to these publications as well as other research and dissemination activities. The collection is continously updated with new and historical material.
2025
Abstract
No abstract has been registered
Authors
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenAbstract
The Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of soy leghemoglobin produced from genetically modified Komagataella phaffii for food uses in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. Soy leghemoglobin produced from genetically modified Komagataella phaffii This application is submitted to gain authorisation for the use of soy leghemoglobin (the liquid preparation is referred to as “LegH Prep”) produced from genetically modified Komagataella phaffii (yeast) as a flavouring (“meaty taste”) in meat analogue products that will be marketed in the European Union (EU). Soy leghemoglobin is intended for addition to meat analogue products that are for use in foods such as burgers, meatballs, and sausages. Komagataella phaffii-strain employed in the production of soy leghemoglobin contains genetic modifications which allow it to express this protein. Following fermentation, the cells are lysed, and the soy leghemoglobin is concentrated by physical means. The soy leghemoglobin is delivered in a liquid preparation (LegH Prep) that is standardised to contain up to 9% soy leghemoglobin on a wet weight basis and a soy leghemoglobin protein purity of at least 65%. The remainder of the protein fraction in the LegH Prep is accounted for by residual proteins from the Komagataella phaffii production strain. These residual proteins are all endogenous to Komagataella phaffii as the gene coding for the expression of soy leghemoglobin is the only gene from a different organism. VKM has assessed the documentation in application EFSA-GMO- NL-2019-162 and EFSA's scientific opinion for the use of soy leghemoglobin produced from genetically modified Komagataella phaffii. The scientific documentation provided in the application is adequate for risk assessment, and in accordance with the EFSA guidance on risk assessment of genetically modified microorganisms for use in food or feed. The VKM GMO Panel does not consider leghemoglobin from genetically modified Komagataella phaffii to imply potential specific health risks in Norway, compared to EU-countries. The EFSA opinion is adequate also for Norwegian considerations. Therefore, a full risk assessment was not performed by VKM. About the assignment: (...)
Authors
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenAbstract
The Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of the genetically modified maize DP51291 for food and feed uses, import and processing in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. Genetically modified maize DP51291 Genetically modified maize DP51291 (application GMFF-2021-0071) was developed via Agrobacterium tumefaciens mediated transformation. DP51291 plants contain the transgenes ipd072Aa and pat which encode the proteins IPD072Aa and PAT (phosphinothricin acetyltransferase). IPD072Aa confers protection against susceptible corn rootworm pests, and the PAT protein confers tolerance to glufosinate herbicide. The phosphomannose isomerase (PMI) protein that was used as a selectable marker. VKM has assessed the documentation in application GMFF-2021-0071 and EFSA's scientific opinion on genetically modified maize DP51291. VKM concludes that the applicant's scientific documentation for the genetically modified maize DP51291 is satisfactory for risk assessment, and in accordance with EFSA guidelines for risk assessment of genetically modified plants for food or feed uses. The genetic modifications in maize DP51291 do not indicate an increased health or environmental risk in Norway compared with EU countries. EFSA's risk assessment is therefore sufficient also for Norwegian conditions. As no specific Norwegian conditions have been identified regarding properties of the genetically modified maize DP51291, VKM's GMO panel has not performed a complete risk assessment of the maize. (...)
Authors
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenAbstract
The Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of the genetically modified maize DAS1131 for food and feed uses, import and processing in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. (link) Genetically modified maize DAS1131 DAS1131 is a genetically modified maize developed by Agrobacterium tumefaciens -mediated transformation. Maize DAS1131 plants contain the transgenes cry1Da2 and dgt-28 epsps which encode the protein Cry1Da2 and the enzyme DGT-28 EPSPS, respectively. Cry1Da2 provides resistance to certain susceptible Lepidopteran (order of butterflies and moths) pests and the enzyme DGT-28 EPSPS provides tolerance to glyphosate-based herbicides. VKM has assessed the documentation in application GMFF-2021-1530 and EFSA's scientific opinion on genetically modified maize DAS1131. VKM concludes that the applicant's scientific documentation for the genetically modified maize DAS1131 is satisfactory for risk assessment, and in accordance with EFSA guidelines for risk assessment of genetically modified plants for food or feed uses. The genetic modifications in maize DAS1131do not indicate an increased health or environmental risk in Norway compared with EU countries. EFSA's risk assessment is therefore sufficient also for Norwegian conditions. As no specific Norwegian conditions have been identified regarding properties of the genetically modified maize DAS1131, VKM's GMO panel has not performed a complete risk assessment of the maize. About the assignment: In stage 1, VKM shall assess the health and environmental risks of the genetically modified organism and derived products in connection with the EFSA scientific hearing of GMO applications. VKM shall review the scientific documentation that the applicant has submitted and possibly provide comments to EFSA. VKM must also consider: i) whether there are specific Norwegian conditions that could give other risks in Norway than those mentioned in the application, ii) whether the Norwegian diet presents a different health risk for the Norwegian population should the GMO be approved, compared to the European population, and iii) risks associated with co-existence with conventional and/or ecologic production of plants for GMOs seeking approval for cultivation. Relevant measures to ensure co-existence must also be considered. In stage 2, VKM shall assess whether comments from Norway have been satisfactorily answered by EFSA. In addition, VKM shall assess whether comments from other countries imply need for further follow-up. (...)
Authors
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Kristian Prydz Volha Shapaval Tage ThorstensenAbstract
The Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of soy leghemoglobin produced from genetically modified Komagataella phaffii for food uses in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. Soy leghemoglobin produced from genetically modified Komagataella phaffii This application is submitted to gain authorisation for the use of soy leghemoglobin (the liquid preparation is referred to as “LegH Prep”) produced from genetically modified Komagataella phaffii (yeast) as a flavouring (“meaty taste”) in meat analogue products that will be marketed in the European Union (EU). Soy leghemoglobin is intended for addition to meat analogue products that are for use in foods such as burgers, meatballs, and sausages. Komagataella phaffii-strain employed in the production of soy leghemoglobin contains genetic modifications which allow it to express this protein. Following fermentation, the cells are lysed, and the soy leghemoglobin is concentrated by physical means. The soy leghemoglobin is delivered in a liquid preparation (LegH Prep) that is standardised to contain up to 9% soy leghemoglobin on a wet weight basis and a soy leghemoglobin protein purity of at least 65%. The remainder of the protein fraction in the LegH Prep is accounted for by residual proteins from the Komagataella phaffii production strain. These residual proteins are all endogenous to Komagataella phaffii as the gene coding for the expression of soy leghemoglobin is the only gene from a different organism. VKM has assessed the documentation in application EFSA-GMO- NL-2019-162 and EFSA's scientific opinion for the use of soy leghemoglobin produced from genetically modified Komagataella phaffii. The scientific documentation provided in the application is adequate for risk assessment, and in accordance with the EFSA guidance on risk assessment of genetically modified microorganisms for use in food or feed. The VKM GMO Panel does not consider leghemoglobin from genetically modified Komagataella phaffii to imply potential specific health risks in Norway, compared to EU-countries. The EFSA opinion is adequate also for Norwegian considerations. Therefore, a full risk assessment was not performed by VKM. About the assignment: (...)
Abstract
No abstract has been registered
Abstract
No abstract has been registered
Authors
Magne Nordang Skårn Chloé Grieu Anne-Grete Roer Hjelkrem Katherine Ann Gredvig Nielsen Silje Kvist Simonsen Nora Steinkopf Anne Kjersti Uhlen Guro BrodalAbstract
Chocolate spot (CS) is one of the most destructive diseases affecting faba beans worldwide, leading to yield reductions of up to 90% in susceptible cultivars under conducive environmental conditions. Traditionally, the disease has been attributed to the fungal pathogens Botrytis fabae and Botrytis cinerea, however recent studies have identified three additional Botrytis species capable of causing the disease. Fungicide applications during flowering are commonly used to control the disease and limit damage to pod set, but this approach is not always effective. The reasons for this lack of control are not fully understood. To increase our understanding of the CS species complex in Norway, we used species-specific PCR to identify different Botrytis species in symptomatic leaves collected at various locations and years. Some Botrytis species are known to be high-risk pathogens for fungicide resistance development, but resistance in Norwegian Botrytis populations in faba bean have not previously been studied. Therefore, we obtained Botrytis isolates from diseased leaves and used a mycelial growth assay to assess their response to the active ingredients (boscalid and pyraclostrobin) in the fungicide commonly used for CS control in Norway. Resistance to both boscalid and pyraclostrobin was detected among B. cinerea isolates, while only resistance to boscalid was detected among B. fabae isolates. To elucidate resistance mechanisms, we analyzed target gene sequences for the presence of mutations known to confer resistance to the two active ingredients. Field experiments were conducted to test the efficacy of various spray timings and fungicides in early and late faba bean varieties. Additionally, we are developing a disease risk model for CS to better understand the conditions that lead to disease and to improve the timing of fungicide applications.
Authors
Magne Nordang Skårn Chloé Grieu Anne-Grete Roer Hjelkrem Katherine Ann Gredvig Nielsen Silje Kvist Simonsen Nora Steinkopf Anne Kjersti Uhlen Guro BrodalAbstract
No abstract has been registered
Abstract
In 2024, spruce bark beetle (Ips typographus) catches decreased in all counties except Telemark, Sør-Trøndelag, and Nordland. The highest catches this year were observed in Telemark and Buskerud. In Telemark, the catches are the highest recorded since the major spruce bark beetle outbreak that started in the mid-1970s. In Buskerud, while catches have declined compared to last year, they remain historically high. In Oppland, the catches have decreased markedly from the record-breaking year of 2023 but remain at moderately high levels. Across Southern Norway, this year’s catches are slightly above the 46-year average. The relatively high catches in Buskerud and Oppland are likely a delayed response to the storm damage in November 2021, as municipalities heavily affected by the storm report especially high catches. Additionally, field reports in 2024 indicate attacks on standing trees in areas with much windfall after the 2021 storm. Many of these damage reports likely pertain to trees attacked by beetles in 2023 or earlier but that are only now showing visible symptoms. The 2024 bark beetle season was characterized by extremely dry and warm weather in May, followed by a very wet summer with normal to slightly below-average temperatures. The warm May weather coincides with the beetles' primary flight period, favoring beetle dispersal and egg-laying. Additionally, the dry conditions in May may have stressed spruce trees, reducing their resistance to beetle attacks. The wet weather later in the summer likely benefited the trees while being sub-optimal for the beetles. Overall, the weather conditions during the 2024 season were probably relatively favorable for the beetles. A temperature-based development model estimate that, by September 17, the spruce bark beetle could have completed two generations near the Oslofjord, along the southern coastline, and in low-lying inland valleys. However, these model results do not necessarily mean that the beetles completed two generations in 2024 but indicate that conditions were warm enough to make it possible.